Piperacillin–tazobactam as alternative to carbapenems for ICU patients

Several studies suggest that alternatives to carbapenems, and particulary beta-lactam/beta-lactamase inhibitor combinations, can be used for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE)-related infections in non-ICU patients. Little is known concerning ICU patients in whom achieving the desired plasmatic pharmacokinetic/pharmacodynamic (PK/PD) target may be difficult. Also, in vitro susceptibility to beta-lactamase inhibitors might not translate into clinical efficacy. We reviewed the recent clinical studies examining the use of BL/BLI as alternatives to carbapenems for therapy of bloodstream infection, PK/PD data and discuss potential ecological benefit from avoiding the use of carbapenems. With the lack of prospective randomized studies, treating ICU patients with ESBL-PE-related infections using piperacillin–tazobactam should be done with caution. Current data suggest that BL/BLI empirical use should be avoided for therapy of ESBL-PE-related infection. Also, definitive therapy should be reserved to patients in clinical stable condition, after microbial documentation and results of susceptibility tests. Optimization of administration and higher dosage should be used in order to reach pharmacological targets.

• Publication year

  2017

• Venue

  Annals of Intensive Care

• Publication date

  2017-11-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s13613-017-0334-xPMID 29127502PMCID 5681454
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.

  2017cited by this paper
• Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials

  2017cited by this paper
• Risk factors for colonization by carbapenemase-producing enterobacteria at admission to a Surgical ICU: A retrospective study.

  2017influential reference
• Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

  2017cited by this paper
• Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial

  2017cited by this paper
• A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae

  2016cited by this paper
• Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.

  2016cited by this paper
• Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.

  2016cited by this paper
• Epidemiology and antimicrobial susceptibility profiles of pathogens causing urinary tract infections in the Asia-Pacific region: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2010-2013.

  2016cited by this paper
• The human microbiota: novel targets for hospital-acquired infections and antibiotic resistance.

  2016cited by this paper
• Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.

  2016cited by this paper
• Colonization and infection with extended-spectrum β-lactamase-producing Enterobacteriaceae in ICU patients: what impact on outcomes and carbapenem exposure?

  2016cited by this paper
• Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.

  2016cited by this paper
• Advances in antibiotic therapy in the critically ill

  2016cited by this paper
• Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

  2016cited by this paper
• Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia

  2016cited by this paper
• Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia.

  2016cited by this paper
• Risk factors for fecal carriage of carbapenemase producing Enterobacteriaceae among intensive care unit patients from a tertiary care center in India

  2016cited by this paper
• Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae

  2016cited by this paper
• Advances in antibiotic therapy in the critically ill

  2016cited by this paper
• Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010-2014.

  2016cited by this paper
• A Systematic Review of the Definitions, Determinants, and Clinical Outcomes of Antimicrobial De-escalation in the Intensive Care Unit.

  2016cited by this paper
• Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections

  2016cited by this paper
• Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae

  2015cited by this paper
• Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization and predictors of mortality: a retrospective study

  2015cited by this paper
• Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae

  2015influential reference
• Risk Factors of Carbapenem-Resistant Klebsiella pneumoniae Infection: A Serious Threat in ICUs

  2015influential reference
• Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.

  2015influential reference
• Forecasting carbapenem resistance from antimicrobial consumption surveillance: Lessons learnt from an OXA-48-producing Klebsiella pneumoniae outbreak in a West London renal unit

  2015influential reference
• Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration.

  2015cited by this paper
• Risk factors of community-onset urinary tract infections caused by plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae.

  2015cited by this paper
• Risk factors for acquisition of carbapenem resistant Enterobacteriaceae in an acute tertiary care hospital in Singapore

  2015cited by this paper
• β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?

  2015cited by this paper
• Multicenter Retrospective Study of Cefmetazole and Flomoxef for Treatment of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Bacteremia

  2015cited by this paper
• Risk factors for colonization with carbapenemase-producing Klebsiella pneumoniae in hospital: a matched case-control study.

  2014influential reference
• Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit

  2014influential reference
• Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial

  2014cited by this paper
• Pharmacokinetic Analysis of Piperacillin Administered with Tazobactam in Critically Ill, Morbidly Obese Surgical Patients

  2014cited by this paper
• Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

  2014cited by this paper
• Aminoglycosides for life-threatening infections: a plea for an individualized approach using intensive therapeutic drug monitoring.

  2014cited by this paper
• The inoculum effect of antibiotics against CTX-M-extended-spectrum β-lactamase-producing Escherichia coli

  2014cited by this paper
• In Vitro Susceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations

  2014cited by this paper
• Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis.

  2014cited by this paper
• Individualization of Piperacillin Dosing for Critically Ill Patients: Dosing Software To Optimize Antimicrobial Therapy

  2014cited by this paper
• Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients

  2014cited by this paper
• Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea: a matched case-control study.

  2014influential reference
• Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012.

  2014influential reference
• Emergence of carbapenem-resistant Klebsiella spp. infections in a Turkish university hospital: epidemiology and risk factors.

  2014influential reference
• Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae: a case-case-control study

  2014cited by this paper
• Aminoglycosides for life-threatening infections: a plea for an individualized approach using intensive therapeutic drug monitoring.

  2014cited by this paper
• Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae

  2014cited by this paper
• Pharmacological Study of Cefoxitin as an Alternative Antibiotic Therapy to Carbapenems in Treatment of Urinary Tract Infections Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli

  2014cited by this paper
• Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients.

  2013cited by this paper
• Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.

  2013cited by this paper
• Impact of the MIC of Piperacillin-Tazobactam on the Outcome of Patients with Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli

  2013cited by this paper
• Emergence of Imipenem-Resistant Gram-Negative Bacilli in Intestinal Flora of Intensive Care Patients

  2013influential reference
• Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.

  2013cited by this paper
• Risk associated with a systematic search of extended-spectrum β-lactamase-producing Enterobacteriaceae.

  2013cited by this paper
• Risk Factors for the First Episode of Klebsiella pneumoniae Resistant to Carbapenems Infection in Critically Ill Patients: A Prospective Study

  2013influential reference
• Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case–control study

  2013influential reference
• Vancomycin-resistant Enterococcus carrier status in the reanimation units and related risk factors.

  2013cited by this paper
• Impact of Antibiotic Use on Carbapenem Resistance in Pseudomonas aeruginosa: Is There a Role for Antibiotic Diversity?

  2013cited by this paper
• Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.

  2012cited by this paper
• Risk factors for KPC-producing Klebsiella pneumoniae bacteremia.

  2012influential reference
• Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli

  2012cited by this paper
• Risk factors for KPC-producing Klebsiella pneumoniae enteric colonization upon ICU admission.

  2012influential reference
• β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.

  2012cited by this paper
• Extended-spectrum β-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy

  2011cited by this paper
• The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria

  2011cited by this paper
• Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections.

  2011cited by this paper
• [Mortality risk factors for bloodstream infections caused by extended-spectrum beta-lactamase-producing microorganisms].

  2011cited by this paper
• Bacteremia Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli Sequence Type ST131 and Non-ST131 Clones: Comparison of Demographic Data, Clinical Features, and Mortality

  2011cited by this paper
• Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case-control study.

  2011influential reference
• Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae.

  2011cited by this paper
• Effect of Antibiotic Treatment on Establishment and Elimination of Intestinal Colonization by KPC-Producing Klebsiella pneumoniae in Mice

  2011cited by this paper
• Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Enterobacter cloacae: Role of Carbapenem Therapy

  2010cited by this paper
• Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.

  2010cited by this paper
• Therapeutic Drug Monitoring of Piperacillin-Tazobactam Using Spent Dialysate Effluent in Patients Receiving Continuous Venovenous Hemodialysis

  2010cited by this paper
• Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae

  2010cited by this paper
• Three Decades of β-Lactamase Inhibitors

  2010cited by this paper
• Epidemiology of extended spectrum beta-lactamase producing Enterobacter bacteremia in a brazilian hospital.

  2010cited by this paper
• Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept.

  2010cited by this paper
• Nationwide survey of extended-spectrum {beta}-lactamase-producing Enterobacteriaceae in the French community setting.

  2009cited by this paper
• Risk Factors and Clinical Impact of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae

  2009influential reference
• Piperacillin penetration into tissue of critically ill patients with sepsis—Bolus versus continuous administration?

  2009cited by this paper
• Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.

  2009cited by this paper
• Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.

  2008cited by this paper
• Predictors of Mortality From Community-Onset Bloodstream Infections Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae

  2008cited by this paper
• Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae: Importance of Inadequate Initial Antimicrobial Treatment

  2007cited by this paper
• Effects of Imipenem-Cilastatin, Ertapenem, Piperacillin-Tazobactam, and Ceftriaxone Treatments on Persistence of Intestinal Colonization by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae Strains in Mice

  2007cited by this paper
• Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.

  2007cited by this paper
• Predictors of Carbapenem-Resistant Klebsiella pneumoniae Acquisition among Hospitalized Adults and Effect of Acquisition on Mortality

  2007influential reference
• Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008

  2007cited by this paper
• Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study.

  2007influential reference
• Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli.

  2006cited by this paper
• Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates.

  2006cited by this paper
• Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli.

  2006cited by this paper
• Effect of Carbapenem Administration on Establishment of Intestinal Colonization by Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice

  2006cited by this paper
• Proteus mirabilis Bloodstream Infections: Risk Factors and Treatment Outcome Related to the Expression of Extended-Spectrum β-Lactamases

  2005cited by this paper
• Acquisition of Resistant Bowel Flora during a Double-Blind Randomized Clinical Trial of Ertapenem versus Piperacillin-Tazobactam Therapy for Intraabdominal Infections

  2005cited by this paper

• β-Lactamase-activated antimicrobial dendron via the amine uncaging strategy

  2025cites this paper
• The whole is greater than the sum of its parts: effect of implementing an ABS consultation service in the ABS program on antibiotic consumption at a tertiary military hospital

  2025cites this paper
• Prospective Audit and Feedback of Targeted Antimicrobials Use at a Tertiary Care Hospital in the United Arab Emirates

  2025cites this paper
• Determining minimal inhibitory concentrations and antibiotic susceptibility for Enterobacterales by flow cytometry using reactive oxygen species as a marker

  2025cites this paper
• Which Classes of Antibiotics Are Associated with the Acquisition of Carbapenemase-Producing Enterobacterales?

  2025cites this paper
• Evaluation of antimicrobial selective pressure using the multicenter semiautomatic surveillance system Japan surveillance for infection prevention and healthcare epidemiology.

  2024cites this paper
• Treatment of infections caused by multidrug-resistant Gram-negative bacilli: a practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.

  2024cites this paper
• Antibiotic susceptibility patterns at the Médecins Sans Frontières (MSF) Acute Trauma Hospital in Aden, Yemen: a retrospective study from January 2018 to June 2021

  2024cites this paper
• Uropathogenic Escherichia coli endeavors: an insight into the characteristic features, resistance mechanism, and treatment choice

  2023cites this paper
• Efficacy of carbapenem vs non carbapenem β-lactam therapy as empiric antimicrobial therapy in patients with extended-spectrum β-lactamase-producing Enterobacterales urinary septic shock: a propensity-weighted multicenter cohort study

  2023cites this paper
• ESBL and carbapenemase-producing Enterobacteriaceae in infectious pleural effusions: current epidemiology at Hôpital du Mali

  2023cites this paper
• Evaluation of the synergistic effect of chitosan metal ions (Cu2+/Co2+) in combination with antibiotics to counteract the effects on antibiotic resistant bacteria

  2023cites this paper
• Effectiveness of third generation cephalosporins or piperacillin compared to cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multicenter retrospective propensity-weighted study.

  2023cites this paper
• Use of Antimicrobials for Bloodstream Infections in the Intensive Care Unit, a Clinically Oriented Review

  2022cites this paper
• Comparative effectiveness of antibiotic therapy for carbapenem-resistant Enterobacterales (CRE) bloodstream infections in hospitalized US veterans.

  2022cites this paper
• Antimicrobial Stewardship Program: Reducing Antibiotic’s Spectrum of Activity Is not the Solution to Limit the Emergence of Multidrug-Resistant Bacteria

  2022cites this paper
• Clinical Failure and Emergence of Resistance during Third Generation Cephalosporin Therapy for Enterobacter spp. Infection: Is the Risk Overestimated? A Prospective Multicentric Study

  2021cites this paper
• Evidence of widespread endemic populations of highly multidrug-resistant Klebsiella pneumoniae seen concurrently through the lens of two hospital intensive care units in Vietnam

  2021cites this paper
• Evaluating the potential for respiratory metagenomics to improve treatment of secondary infection and detection of nosocomial transmission on expanded COVID-19 intensive care units

  2021cites this paper
• Genetic Diversity of Some Proteus mirabilis Strains Isolated from Gastric Discorded Egyptian Patients.

  2020cites this paper
• Infections caused by naturally AmpC-producing Enterobacteriaceae: can we use third generation cephalosporins? A narrative review.

  2020cites this paper
• Costs and Outcomes of Patients Admitted to the Intensive Care Unit With Cancer

  2020cites this paper
• Application of respiratory metagenomics for COVID-19 patients on the intensive care unit to inform appropriate initial antimicrobial treatment and rapid detection of nosocomial transmission

  2020cites this paper
• Non-Carbapenem Antibiotics to Treat Severe Extended-Spectrum- (cid:12) - Lactamase-Producing Enterobacteriaceae Infections in Intensive Care Unit Patients

  2020cites this paper
• Current Susceptibility Trend of Antibiotics in a Tertiary Care Hospital - Need to Emphasize on Alternate Therapeutic Agents

  2019cites this paper
• Re-Potentiation of β-Lactam Antibiotic by Synergistic Combination with Biogenic Copper Oxide Nanocubes against Biofilm Forming Multidrug-Resistant Bacteria

  2019cites this paper
• Quel traitement des infections à BLSE en réanimation ?

  2019cites this paper
• Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel β-Lactamase Inhibitor Enmetazobactam

  2019cites this paper
• Use of non-carbapenem antibiotics to treat severe extended-spectrum β-lactamase-producing Enterobacteriaceae infections in intensive care unit patients.

  2019cites this paper
• Multicentre randomised controlled trial to investigate usefulness of the rapid diagnostic βLACTA test performed directly on bacterial cell pellets from respiratory, urinary or blood samples for the early de-escalation of carbapenems in septic intensive care unit patients: the BLUE-CarbA protocol

  2019cites this paper
• Interplay between β-lactamases and new β-lactamase inhibitors

  2019cites this paper
• Treatment of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBLs) infections: what have we learned until now?

  2018cites this paper
• Place des référents en antibiothérapie en réanimation

  2018cites this paper
• Extensively-drug-resistant bacteria carriers among overseas travellers: one-third had not been hospitalized previously.

  2018cites this paper
• Ventilator-associated pneumonia related to ESBL-producing gram negative bacilli.

  2018cites this paper
• Implementer resistance to school food policy: unpacking the paradox

  2018cites this paper
• Sepsis and Septic Shock Strategies.

  2017cites this paper
• Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.

  2017cites this paper